Axsome Therapeutics, Inc. (AXSM) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $209.67 (+2.74%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 23, 2026 | Rudy Li | Wolfe Research | $230.00 | +9.7% |
| Feb 23, 2026 | Joon Lee | Truist Financial | $200.00 | -4.6% |
| Jan 21, 2026 | Leonid Timashev | RBC Capital | $219.00 | +4.4% |
| Jan 5, 2026 | Ami Fadia | Needham | $225.00 | +7.3% |
| Jan 5, 2026 | Raghuram Selvaraju | H.C. Wainwright | $200.00 | -4.6% |
| Jan 2, 2026 | Yatin Suneja | Guggenheim | $205.00 | -2.2% |
| Dec 31, 2025 | Graig Suvannavejh | Mizuho Securities | $217.00 | +3.5% |
| Dec 31, 2025 | Jay Olson | Oppenheimer | $220.00 | +4.9% |
| Oct 20, 2025 | Sean Laaman | Morgan Stanley | $194.00 | -7.5% |
| May 6, 2025 | Joel Beatty | Robert W. Baird | $162.00 | -22.7% |
| Mar 27, 2025 | Graig Suvannavejh | Mizuho Securities | $216.00 | +3.0% |
| Feb 3, 2025 | Graig Suvannavejh | Mizuho Securities | $137.00 | -34.7% |
| Feb 3, 2025 | Joon Lee | Truist Financial | $190.00 | -9.4% |
| Feb 3, 2025 | Joel Beatty | Robert W. Baird | $132.00 | -37.0% |
| Nov 12, 2024 | Yatin Suneja | Guggenheim | $135.00 | -35.6% |
| Sep 11, 2024 | Graig Suvannavejh | Mizuho Securities | $106.00 | -49.4% |
| Sep 3, 2024 | Cerena Chen | Wells Fargo | $140.00 | -33.2% |
| Aug 6, 2024 | Raghuram Selvaraju | H.C. Wainwright | $180.00 | -14.2% |
| Aug 6, 2024 | Jason Gerberry | Bank of America Securities | $106.00 | -49.4% |
| Jul 22, 2024 | Leonid Timashev | RBC Capital | $131.00 | -37.5% |
Top Analysts Covering AXSM
AXSM vs Sector & Market
| Metric | AXSM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.08 | 2.25 | 2.42 |
| Analyst Count | 25 | 8 | 18 |
| Target Upside | +28.1% | +16187.2% | +19.5% |
| P/E Ratio | -51.14 | 3.84 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $916M | $985M | $1.03B | 17 |
| 2027-03-31 | $269M | $311M | $336M | 6 |
| 2027-06-30 | $311M | $360M | $388M | 6 |
| 2027-09-30 | $346M | $400M | $432M | 6 |
| 2027-12-31 | $393M | $454M | $490M | 6 |
| 2028-03-31 | $317M | $367M | $396M | 6 |
| 2028-06-30 | $411M | $476M | $514M | 5 |
| 2028-09-30 | $483M | $559M | $603M | 5 |
| 2028-12-31 | $603M | $698M | $754M | 6 |
| 2029-12-31 | $2.35B | $2.80B | $3.33B | 11 |
| 2030-12-31 | $2.78B | $3.32B | $3.95B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-3.80 | $-0.86 | $0.90 | 13 |
| 2027-03-31 | $0.47 | $0.57 | $0.63 | 2 |
| 2027-06-30 | $0.88 | $1.07 | $1.18 | 2 |
| 2027-09-30 | $1.24 | $1.50 | $1.66 | 2 |
| 2027-12-31 | $1.68 | $2.04 | $2.24 | 2 |
| 2028-03-31 | $1.99 | $2.42 | $2.67 | 3 |
| 2028-06-30 | $2.58 | $3.13 | $3.46 | 3 |
| 2028-09-30 | $3.02 | $3.67 | $4.05 | 3 |
| 2028-12-31 | $3.73 | $4.53 | $5.00 | 3 |
| 2029-12-31 | $16.99 | $21.54 | $26.82 | 11 |
| 2030-12-31 | $21.35 | $27.07 | $33.71 | 5 |
Frequently Asked Questions
What is the analyst consensus for AXSM?
The consensus among 25 analysts covering Axsome Therapeutics, Inc. (AXSM) is Buy with an average price target of $262.38.
What is the highest price target for AXSM?
The highest price target for AXSM is $230.00, set by Rudy Li at Wolfe Research on 2026-02-23.
What is the lowest price target for AXSM?
The lowest price target for AXSM is $25.00, set by Ashwani Verma at Bank of America Securities on 2021-08-10.
How many analysts cover AXSM?
25 analysts have issued ratings for Axsome Therapeutics, Inc. in the past 12 months.
Is AXSM a buy or sell right now?
Based on 25 analyst ratings, AXSM has a consensus rating of Buy (2.08/5) with a +28.1% upside to the consensus target of $262.38.
What are the earnings estimates for AXSM?
Analysts estimate AXSM will report EPS of $-0.86 for the period ending 2026-12-31, with revenue estimated at $985M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.